Bicycle Therapeutics Statistics
Total Valuation
BCYC has a market cap or net worth of $277.15 million. The enterprise value is -$266.99 million.
| Market Cap | 277.15M |
| Enterprise Value | -266.99M |
Important Dates
The last earnings date was Thursday, July 30, 2026, before market open.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCYC has 69.81 million shares outstanding. The number of shares has increased by 0.52% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 69.81M |
| Shares Change (YoY) | +0.52% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 1.28% |
| Owned by Institutions (%) | 39.07% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.53 |
| Forward PS | 19.96 |
| PB Ratio | 0.50 |
| P/TBV Ratio | 0.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,089.64 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -20.68% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 12.06% |
| Revenue Per Employee | $212,517 |
| Profits Per Employee | -$661,153 |
| Employee Count | 288 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BCYC has paid $1.73 million in taxes.
| Income Tax | 1.73M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.49% in the last 52 weeks. The beta is 1.53, so BCYC's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | -49.49% |
| 50-Day Moving Average | 4.16 |
| 200-Day Moving Average | 5.52 |
| Relative Strength Index (RSI) | 44.47 |
| Average Volume (20 Days) | 314,789 |
Short Selling Information
The latest short interest is 2.98 million, so 7.67% of the outstanding shares have been sold short.
| Short Interest | 2.98M |
| Short Previous Month | 2.88M |
| Short % of Shares Out | 7.67% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.77 |
Income Statement
In the last 12 months, BCYC had revenue of $61.21 million and -$190.41 million in losses. Loss per share was -$2.74.
| Revenue | 61.21M |
| Gross Profit | -127.85M |
| Operating Income | -206.10M |
| Pretax Income | -188.68M |
| Net Income | -190.41M |
| EBITDA | -205.01M |
| EBIT | -210.30M |
| Loss Per Share | -$2.74 |
Balance Sheet
The company has $559.47 million in cash and $15.34 million in debt, with a net cash position of $544.14 million or $7.79 per share.
| Cash & Cash Equivalents | 559.47M |
| Total Debt | 15.34M |
| Net Cash | 544.14M |
| Net Cash Per Share | $7.79 |
| Equity (Book Value) | 554.32M |
| Book Value Per Share | 7.95 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was -$229.23 million and capital expenditures -$2.46 million, giving a free cash flow of -$231.69 million.
| Operating Cash Flow | -229.23M |
| Capital Expenditures | -2.46M |
| Depreciation & Amortization | 5.35M |
| Net Borrowing | -191,000 |
| Free Cash Flow | -231.69M |
| FCF Per Share | -$3.32 |
Margins
| Gross Margin | -208.89% |
| Operating Margin | -336.74% |
| Pretax Margin | -308.28% |
| Profit Margin | n/a |
| EBITDA Margin | -334.96% |
| EBIT Margin | -343.60% |
| FCF Margin | n/a |
Dividends & Yields
BCYC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.52% |
| Shareholder Yield | -0.52% |
| Earnings Yield | -68.70% |
| FCF Yield | -83.60% |
Analyst Forecast
The average price target for BCYC is $9.86, which is 148.36% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.86 |
| Price Target Difference | 148.36% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -40.08% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |